Influenza -Like Illness
Conditions
Brief summary
This is a Phase 2b, multi-center, double-blind, randomized, placebo-controlled, parallel-group study of NKT versus placebo in otherwise healthy adults presenting with acute uncomplicated ILI due to influenza or other respiratory viruses in a community setting.
Interventions
DRUGNorketotifen
Oral capsule
DRUGPlacebo
Oral capsule
Sponsors
Emergo Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
1. Able to understand the study and comply with all study procedures, and willing to provide written informed consent prior to the pre-dose examinations 2. Symptoms of ILI including all of the following: * Fever ≥38º Celsius (oral) in the predose examinations or \>4 hours after dosing of antipyretics if they were taken * At least one of the following general systemic symptoms associated with ILI are present with a severity of moderate or greater: headache, feverishness or chills, muscle or joint pain, fatigue * At least one of the following respiratory symptoms associated with ILI are present with a severity of moderate or greater: cough, sore throat, nasal congestion 3. The time interval between the onset of symptoms and the predose examinations is ≤96 hours. The onset of symptoms is defined as either: * Time of the first increase in body temperature (an increase of at least 1º Celsius from normal body temperature) * Time when the subject experiences at least one general or respiratory symptom 4. Females of childbearing potential and males agree to use an appropriate method of contraception as detailed in the protocol
Exclusion criteria
1. Female subjects who are pregnant, 2 weeks post-partum, or breastfeeding 2. Severe ILI requiring inpatient treatment 3. Any of the following risk factors (according to the CDC's list of People at High Risk for Developing Serious Flu-Related Complications): * Residents of nursing homes or other long-term care facilities * American Indians and Alaska natives * Asthma * Chronic lung disease (such as chronic obstructive pulmonary disease or cystic fibrosis) * Neurological and neurodevelopmental conditions (including disorders of the brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy \[seizure disorders\], stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury) * Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease) * Blood disorders (such as sickle cell disease) * Endocrine disorders (such as diabetes mellitus) * Kidney disorders * Liver disorders * Metabolic disorders (such as inherited metabolic disorders and mitochondrial disorders) * Compromised immune system due to disease or medication (such as subjects with human immunodeficiency virus or cancer, or those on chronic steroids) * Extreme obesity (body mass index ≥40 kg/m\^2) 4. Presence of any severe or uncontrolled medical or psychiatric illness 5. History of or current autoimmune disease 6. History of recurrent lower respiratory tract infection 7. Any concurrent infection requiring systemic antimicrobial and/or antiviral therapy 8. Female subjects who are pregnant or breastfeeding 9. Any clinically significant electrocardiogram test 10. Received baloxavir, oseltamivir, peramivir, zanamivir, rimantadine, or amantadine within 30 days prior to the pre-dose examinations 11. Received an investigational monoclonal antibody for a viral disease in the last year prior to the pre-dose examinations 12. Received ketotifen fumarate, cromolyn sodium, or nedocromil sodium by any route of administration within 30 days prior to the pre-dose examinations 13. Exposure to an investigational drug within 30 days prior to the pre-dose examinations 14. History of allergic reaction to ketotifen 15. Any prior exposure to norketotifen
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to alleviation of symptoms | 14 days | Time to alleviation of the symptoms of ILI (headache, feverishness/chills, muscle/joint pain, fatigue, cough, sore throat, nasal congestion) |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in composite symptom score at each time point through Day 5 | 5 days |
| Time to resolution of fever (body temperature equal to or less than 37ºC) | 14 days |
| Body temperature at each time point through Day 5 | 5 days |
| Proportion of subjects whose symptoms have been alleviated at each time point through Day 5 | 5 days |
| Time to resumption of normal activity | 14 days |
| Use of rescue medication (acetaminophen) | 14 days |
| Time to alleviation of individual symptoms (headache, feverishness/chills, muscle/joint pain, fatigue, cough, sore throat, nasal congestion) | 14 days |
Countries
United States
Outcome results
None listed